Nanjing Chuangte to Present at ACCESS CHINA Boston Forum

May 26th, 2023 (Shanghai) — We are glad to announce that Yongqiang Zhu, the CEO of Nanjing Chuangte, has been invited to present at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.

Please contact us if you would like to have 1 on 1 meeting with Nanjing Chuangte.

About Nanjing Chuangte

Nanjing Chuangte Pharmaceutical Technology Co., Ltd. was founded in February 2019. The company is an innovative biotech company specializing in research and development of new drugs. With the enterprise mission of “Health for the public, benefit for the world”, Nanjing Chuangte focus on cancers, cardiovascular and respiratory diseases, and are committed to providing innovative products so as to consistently provide patients with health services, and create value for customers.

The company attaches great importance to R&D innovation and talent introduction, with research and management team of around 40 people. 80% of team members hold the Ph.D./master degrees. The company also employed professors, researchers, senior engineers and many scientific consultants.

The pipeline comprises 19 new drugs in development, with 3 new drugs in clinical trials and all drugs are showing satisfactory data in clinical trials.





About the speaker

Dr. Yongqiang Zhu founded Nanjing Chuangte in February 2019 as the CEO, dedicated to the design and research of new drugs. Dr. Zhu has experience in drug research and development for more than 20 years, and has chaired a number of national and provincial major science and technology projects. In total, 16 clinical approvals were obtained for new drugs (including 3 new drugs of category 1), with one new drug in phase III clinical study, and one new drug been approved for clinical trials both by the FDA and NMPA.

Dr. Zhu received the Bachelor’s degree in Chemistry from Sichuan University, Master’s degree in Organic Chemistry from Huazhong University of Science and Technology, and Ph.D. from Peking University. After that, he joined the Pharmaceutical Research Institute of Simcere as director of the Pharmaceutical Chemistry Laboratory. He then joined Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. Afterwards he worked as a postdoctoral researcher in the University of Michigan in professor Wang Shaomeng’s team.

Dr Zhu has extensive experience in design of targeted drug and research on drug action at the molecular level, as well as management of a corporate.





About ACCESS CHINA Boston Forum

“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.

Conference Name: ACCESS CHINA – Boston Forum @BIO

Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)

Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception

Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows

Participants: Pharma/Biotech senior management and BDs, investors.

View more information at https://biotochina.org/


 “ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间,药通中国已成功举办13届线上线下活动,帮助近千家公司在药通平台上展出。


大会日期:2023.6.4(周日,波士顿) 2023.6.13-15(线上)


大会规模:预计线上1000参会者; 线下150参会者; 100场公司路演


查看更多信息: https://biotochina.org/


This image has an empty alt attribute; its file name is ACbostonkv_01.png

Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang